Spots Global Cancer Trial Database for A Combination of Abraxane and Cisplatin in Metastatic Breast Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Combination of Abraxane and Cisplatin in Metastatic Breast Cancer
Official Title: A Single Institutional Phase II Clinical Trial of Abraxane Combined With Cisplatin in Metastatic Breast Cancer
Study ID: NCT01149798
Conditions
Interventions
Study Description
Brief Summary: This phase II trial on the assumption that abraxane and cisplatin combination therapy is efficacy in metastatic breast cancer.
Detailed Description: The rationales for the combination of Abraxane and cisplatin include that either drug has antitumor activity; they have different mechanisms; no cross-resistance are documented between them, and there have been some preclinical evidences indicating synergistic effects between the two agents. This phase II study will be undertaken to evaluate combination of cisplatin and weekly abraxane in terms of efficacy and safety in MBC patients.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Fudan University Cancer Hospital, Shanghai, , China
Contact Details
Name: Xichun Hu
Affiliation: Fudan University
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
